立方制药非奈利酮原料药上市申请获受理

Core Viewpoint - The company has received a notice from the National Medical Products Administration regarding the acceptance of the marketing application for Finerenone, a novel non-steroidal selective mineralocorticoid receptor antagonist (MRA) [1] Group 1 - Finerenone is indicated for adult patients with chronic kidney disease associated with type 2 diabetes, aimed at reducing the risk of sustained decline in eGFR and end-stage renal disease [1]